Journal article

Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer

Benjamin B Williams, Meg Wall, Rebecca Yu Miao, Brenda Williams, Ivan Bertoncello, Michael H Kershaw, Theo Mantamadiotis, Michelle Haber, Murray D Norris, Anand Gautam, Phillip K Darcy, Robert G Ramsay

CANCER IMMUNOLOGY IMMUNOTHERAPY | SPRINGER | Published : 2008

Abstract

Overexpression of the proto-oncogene c-Myb occurs in more than 80% of colorectal cancer (CRC) and is associated with aggressive disease and poor prognosis. To test c-Myb as a therapeutic target in CRC we devised a DNA fusion vaccine to generate an anti-CRC immune response. c-Myb, like many tumor antigens, is weakly immunogenic as it is a "self" antigen and subject to tolerance. To break tolerance, a DNA fusion vaccine was generated comprising wild-type c-Myb cDNA flanked by two potent Th epitopes derived from tetanus toxin. Vaccination was performed targeting a highly aggressive, weakly immunogenic, subcutaneous, syngeneic, colon adenocarcinoma cell line MC38 which highly expresses c-Myb. Pr..

View full abstract